图书简介
Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field.
馆藏图书馆
Harvard Library
1 Pedro Romero and Pierre G. Coulie: Adaptive T-cell immunity and tumor antigen recognition; 2 Gail D. Sckisel, Arta M. Monjazeb, Annie Mirsoian, Anthony E. Zamora, Steven Grossenbacher, and William J. Murphy: Impact of aging and body mass on cancer immunotherapy outcomes; 3 Thomas C.C. Tan, Jean-Marc Doisne and Francesco Colucci: The potential of natural killer cells in cancer immunotherapy; 4 Russell Hughes and Munitta Muthana: The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy; 5 Natalia Aptsiauri, Angel M. Garcia-Lora, Federico Garrido: Hard and soft loss of MHC class I expression in cancer cells; 6 A.G. Dalgleish: Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses; 7 Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg: Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.; 8 Thomas J. Sayers and Neil A Cross: Triggering death receptors as a means of inducing tumoricidal activity; 9 Jayakumar Vadakekolathu, Stephanie B. McArdle, David J. Boocock, and Amanda Miles: Identification of tumor antigens for clinical evaluation; 10 Peter L. Stern and Kenneth Oguejiofor: Viral antigens as targets for prophylactic and therapeutic intervention in cancer; 11 Constantin N. Baxevanis and Sonia A. Perez: HER-2/neu as a target for vaccine and antibody directed therapies; 12 Matteo Bellone, Sara Martina Parigi, and Elena Jachetti: Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model; 13 Per thor Straten, Dave Schrama, Jurgen C. Becker and Mads Hald Andersen: Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy; 14 M. Strioga and E. Tartour: Predictive biomarkers to better select patients for cancer immunotherapy; 15 Karishma Rajani, Vanessa Alonso-Camino, Nicolas Boisgerault, Richard Vile: Viral platforms for expression of tumour antigens in cancer immunotherapy; 16 Paul Moss: Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies; 17 L. G. Durrant, W. Xue, L. R. Machado, R. L. Metheringham, and V. A. Brentville: DNA vaccines; 18 Uzoma K. Iheagwaraa, Pamela L. Beattya, Chan Su-Wan Biancaa, Lora H. Rigattid, Ted Ross, and Olivera J. Finn: Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA); 19 Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-Ann Guinn: Vaccination against myeloid leukaemias using newly defined antigens; 20 Patrick A. Ott and F. Stephen Hodi: Immune-checkpoint blockade in cancer immunotherapy; 21 Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter: Multi-peptide cancer vaccines for clinical application; 22 Marco Donia, Eva Ellebaek, and Inge Marie Svane: Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma; 23 John S. Bridgeman and David E. Gilham: Chimeric antigen receptor gene therapy in cancer; 24 Claire Deligne, Sophie Siberil, and Jean-Luc Teillaud: The vaccinal effect of monoclonal antibodies in cancer therapy; 25 Gabriele Multhoff and Michael Stanglmaier: Antibody therapies: defining appropriate cell surface epitopes for targeting tumours; 26 Sophie Derniame and Aurore Saudemont: Adoptive lymphocyte (stem cell) therapy in cancer; 27 Tarik Regad and Morgan G. Mathieu: Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy; 28 Ludmila Muller and Graham Pawelec: Immune escape and aging of the immune system compromises the immune response to tumor antigens
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐